NCT05065619

Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

A Phase I/II, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of MT-2766 in Japanese Adults (COVID-19)

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 128 (actual)
• Sponsor: Medicago · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Accepted

Summary

The objective of this study is to evaluate the safety and immunogenicity of MT-2766 in Japanese adults.

Conditions

• SARS-CoV-2 Infection

Interventions

Type	Name	Description
BIOLOGICAL	MT-2766 High dose (3.75 µg)	Subjects will receive two doses of MT-2766 high dose (3.75 µg) given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
DRUG	Placebo	Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
BIOLOGICAL	MT-2766 Low dose	Subjects will receive two doses of MT-2766 low dose given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)

Timeline

• Start date: 2021-10-02
• Primary completion: 2022-03-12
• Completion: 2023-01-29
• First posted: 2021-10-04
• Last updated: 2023-11-07
• Results posted: 2023-05-01

Locations

3 sites across 1 country: Japan

Regulatory

• FDA-regulated drug study